March 25th, 2003 - Volume 25 - Issue 6
pp: 4-44

PDF Only



Ovarian Cancer: Adjuvant Chemo Reduces Recurrence, But So Does Adequate Staging

Carlson, Robert H.

Oncology Times. 25(6):5-7, March 25th, 2003.

The standard of care for high-risk early ovarian cancer is adjuvant chemotherapy after surgery, but the big question is which patients are at high risk, something that is not always obvious. The large ACTION and ICON1 European Phase III studies have now been reported, but the question remains open.

Liability Reform Legislation is Back. Sen. Grassley Promises This Time It Will Win Passage in Senate

Eastman, Peggy

Oncology Times. 25(6):11-14, March 25th, 2003.

The Chairman of the Senate Finance Committee, also a member of the Senate Judiciary Committee, has pledged to do all he can to pass medical malpractice reform. “Our situation is so bad I'll vote for broad tort reform, weak tort reform, whatever we can get passed,” he says.

Anemia Hard Choices: Comparing Procrit vs Aranesp

Henkel, Gretchen

Oncology Times. 25(6):29-30,32-33, March 25th, 2003.

With no clear consensus about one drug being superior to the other, the Centers for Medicare & Medicaid Services, researchers, and drug companies are all weighing in on what may be an “apples vs oranges” debate.



Colorectal Cancer: Tailored Approaches with PCR Analysis Promise Better Outcomes

Goodman, Alice

Oncology Times. 25(6):16-18,23, March 25th, 2003.

Research discoveries are paving the way for customized chemotherapy for colorectal cancer, entailing individualized therapy based on molecular knowledge about the patient's tumor as well as normal tissue. Evidence for inter-individual differences is illustrated by differences in response to 5-FU, as well as newer drugs.


Third Submission Is Charm for Study of Intraperitoneal Hyperthermic Chemotherapy

Henkel, Gretchen

Oncology Times. 25(6):34-35, March 25th, 2003.

When submitting even positive studies for journal publication, it pays to be tenacious, says the author of a study of IP hyperthermic chemotherapy combined with mitomycin C after cytoreductive surgery in patients with peritoneal carcinomatosis.